Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • National Prescription Drug Take Back Day Slated for April 28

    by
    • Optum Workers' Comp
    | Apr 17, 2018
    Tag Icon
    Overdose, DEA
    Saturday, April 28, from 10 a.m. to 2 p.m., is National Prescription Drug Take Back Day sponsored by the U.S. Drug Enforcement Administration (DEA). The purpose of National Prescription Drug Take Back Day is to provide a safe, convenient, and responsible way to dispose of prescription medications that are unwanted, unused, or expired, while also educating the public on the potential abuse of medications.


  • FDA advisory committee recommends approval of lofexidine for opioid withdrawal symptoms

    by
    • Optum Workers' Comp
    | Apr 06, 2018
    Tag Icon
    Opioids, FDA
    An advisory committee of the U.S. Food and Drug Administration (FDA) voted to approve a non-opioid, lofexidine hydrochloride, to alleviate the symptoms of abrupt opioid withdrawal. Lofexidine, an alpha-2 adrenergic agonist that works by reducing the release of norepinephrine, is similar to clonidine, which has been used off-label for the management of opioid withdrawal symptoms. According to this report, lofexidine has been found to be safe and effective in reducing symptoms of nausea, vomiting, anxiety, diarrhea and the overall feeling of sickness during withdrawal. Lofexidine has been marketed in the United Kingdom (UK) as BritLofex since 1992 to relieve symptoms in patients undergoing opioid detoxification.


  • Safety concerns regarding sterile compounded products from Cantrell Drug Company

    by
    • Optum Workers' Comp
    | Mar 14, 2018
    Tag Icon
    Compounded Medications, recall, FDA
    The U.S. Food and Drug Administration (FDA) issued a warning to health care professionals and is urging consumers to stop using sterile products, including opioid products and other medications intended for sterile injection, produced by Cantrell Drug Company in Little Rock, Arkansas. According to the FDA, they are “concerned about serious deficiencies in Cantrell’s compounding operations, including its processes to ensure quality and sterility assurance that put patient safety at risk.” If compounded injectable products are not sterile and are prepared in non-sterile environments, administering the medications to patients can result in serious, possibly life-threatening infections.


  • FDA approves Apadaz™ - new short-acting opioid analgesic for acute pain

    by
    • Optum Workers' Comp
    | Mar 01, 2018
    Tag Icon
    Opioids, FDA
    KemPharm, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz (benzhydrocodone and acetaminophen), an immediate-release (short-acting) opioid analgesic combination product. Apadaz is intended for the short-term (no more than 14 days) management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.